Need Help?

Whole Genome Sequencing Data of High Grade Serous Ovarian Cancer

Longitudinal whole genome sequencing data to study chemoresponse in ovarian cancer. These samples belong to an ongoing sample collection and the data already includes hundreds of samples from over 200 patients. Samples are from primary and metastatic tissues and ascites. All patients have been treated with platinum-taxane based chemotherapy and majority of them are diagnosed with high-grade serous ovarian cancer.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001009738 unspecified 6
EGAD00001009791 HiSeq X Ten 20
EGAD00001009888 HiSeq X Ten 55
EGAD00001010019 HiSeq X Ten unspecified 58
EGAD00001010029 HiSeq X Ten 78
EGAD00001010066 HiSeq X Ten -
EGAD00001010202 HiSeq X Ten unspecified 90
EGAD00001010845 unspecified 77
EGAD00001011086 unspecified 59
EGAD00001011304 HiSeq X Ten unspecified 84
EGAD00001011353 unspecified 11
EGAD00001011368 Illumina NovaSeq 6000 112
EGAD50000000177 unspecified 48
EGAD50000000211 Illumina NovaSeq 6000 65
EGAD50000000275 Illumina NovaSeq 6000 208
EGAD50000000313 Illumina NovaSeq 6000 89
Publications Citations
Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer.
NPJ Precis Oncol 6: 2022 96 		7
Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes.
Clin Cancer Res 29: 2023 3110-3123 		3
H&E image analysis pipeline for quantifying morphological features.
J Pathol Inform 14: 2023 100339 		0
Genome-wide quantification of copy-number aberration impact on gene expression in ovarian high-grade serous carcinoma.
BMC Cancer 24: 2024 173 		0